Patents by Inventor Sheri J. Olson

Sheri J. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140302494
    Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
    Type: Application
    Filed: April 23, 2012
    Publication date: October 9, 2014
    Applicant: Myriad Genetics, Incorporated
    Inventors: Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
  • Publication number: 20130280703
    Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
    Type: Application
    Filed: April 23, 2012
    Publication date: October 24, 2013
    Applicant: Myriad Genetics, Incorporated
    Inventors: Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
  • Publication number: 20090325238
    Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
    Type: Application
    Filed: May 15, 2009
    Publication date: December 31, 2009
    Applicant: Ore Pharmaceuticals Inc.
    Inventors: Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
  • Publication number: 20090325237
    Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
    Type: Application
    Filed: May 15, 2009
    Publication date: December 31, 2009
    Applicant: Ore Pharmaceuticals Inc.
    Inventors: Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
  • Publication number: 20090269814
    Abstract: Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2(omi 1-5) and the ten polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene and/or protein sequence, determine the presence of a normal sequence, and of mutations of BRCA2. This invention is also related to a method of performing gene therapy with BRCA2(omi 1-5) coding sequences or fragments thereof. This invention is further related to protein therapy with BRCA2(omi 1-5) proteins or their functional equivalents.
    Type: Application
    Filed: March 11, 2009
    Publication date: October 29, 2009
    Inventors: Patricia D. Murphy, Marga B. White, Mark B. Rabin, Sheri J. Olson, Matthew Yoshikawa, Geoffrey M. Jackson, Tara Eskandari, Brenda Schryer, Michael Park
  • Patent number: 6838256
    Abstract: isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: January 4, 2005
    Assignee: Gene Logic Inc.
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
  • Patent number: 6686163
    Abstract: The invention is directed to isolated coding sequences and to the protein sequences they code for. The coding sequence for BRCA1(omi4) gene is provided together with the protein sequence it codes for. The BRCA1(omi4) sequence is used for identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because the patient has an inherited causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with the isolated BRCA1(omi4) coding sequence and protein replacement therapy with the BRCA1(omi4) protein.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: February 3, 2004
    Assignee: Gene Logic Inc.
    Inventors: Antonette C. P. Allen, Tracy S. Angelly, Tammy Lawrence, Sheri J. Olson, Mark B. Rabin
  • Publication number: 20030027166
    Abstract: The invention is directed to isolated coding sequences and to the protein sequences they code for. The coding sequence for BRCA1(omi4) gene is provided together with the protein sequence it codes for. The BRCA1(omi4) sequence is used for identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because the patient has an inherited causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with the isolated BRCA1(omi4) coding sequence and protein replacement therapy with the BRCA1(omi4) protein.
    Type: Application
    Filed: December 20, 2001
    Publication date: February 6, 2003
    Applicant: OncorMed Inc.
    Inventors: Antonette C.P. Allen, Tracy S. Angelly, Tammy Lawrence, Sheri J. Olson, Mark B. Rabin
  • Publication number: 20030022184
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA1(omi) proteins or their functional equivalent.
    Type: Application
    Filed: October 22, 2001
    Publication date: January 30, 2003
    Applicant: OncorMed. Inc.
    Inventors: Patricia D. Murphy, Antonette C.P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng
  • Publication number: 20020183268
    Abstract: Isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
    Type: Application
    Filed: December 13, 2000
    Publication date: December 5, 2002
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
  • Patent number: 6130322
    Abstract: This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2), and BRCA1.sup.(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA.sup.(omi) proteins or their functional equivalent.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: October 10, 2000
    Assignee: Gene Logic, Inc.
    Inventors: Patricia D. Murphy, Antonette C. P. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise Thurber, Bin Zeng
  • Patent number: 5750400
    Abstract: This invention is directed to three coding sequences of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2) and BRCA1.sup.(omi3) as well as their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: May 12, 1998
    Assignee: OncorMed, Inc.
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
  • Patent number: 5654155
    Abstract: A consensus DNA sequence has been determined for the BRCA1 gene. As has been seven polymorphic sites and their rates of occurrence in normal BRCA1 genes. The consensus gene BRCA1.sup.(omi) and the seven polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene, determine the presence of a normal gene, and of mutations, and to classify tumors.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: August 5, 1997
    Assignee: OncorMed, Inc.
    Inventors: Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng